Title

Simultaneous Determination of 15 Pteridines using Capillary Electrophoresis-- Laser-Induced Fluorescence

Presenter Information

Emily King

Department

Chemistry

Major

Chemistry

Research Advisor

Ma, Yinfa

Advisor's Department

Chemistry

Funding Source

Research is supported by First Year Research Experience funding Colleague of Arts, Sciences, and Business, and the Department of Chemistry

Abstract

Cancer is the second leading cause of death worldwide and it is the cause of about 13% of all deaths worldwide. Deaths from cancer worldwide are projected to continue rising, with an estimated 12 million deaths per year in 2030. Therefore early diagnosis of cancer has become an important task worldwide since it can significantly enhance the cure rate. To achieve early diagnosis of cancers, biomarkers, which are the indicators of existing cancer in human body, must be identified and their correlation with cancer development must be established.

This research project will build upon and validate the previously developed analytical method for the simultaneous determination of a fifteen pteridine panel using our proprietary P-Scan technology. Elevated levels of pteridine derivatives in the urine of women diagnosed with breast cancer has established these molecules as putative biomarkers for early risk screening. However, the sensitivity and accuracy must be improved to minimize false-positive and false-negative rates when it is applied in clinical diagnosis. This expanded biomarker panel study is intended to increase diagnostic accuracy. The impact of this study is that the resulting data and method will broaden the panel of metabolic biomarkers, enabling researchers and clinicians to more accurately characterize tumor biology in cancer patients.

Biography

Emily King is a high school graduate from St. Vincent de Paul High School in Perryville, Missouri. Currently, Emily is a freshman majoring in Chemistry and has received the William H. Webb, Trustees, University, Dean’s, and Women in Engineering scholarships as well as Bright Flight. Emily is a member of the Honors Academy, has been accepted into the First Year Research Experience program, and is on the Dean’s List. Her research concerns bioanalytical methods of cancer metabolite detection in urine, conducted under the guidance of Dr. Yinfa Ma and Casey Burton, within the center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring.

Research Category

Sciences

Presentation Type

Oral Presentation

Document Type

Presentation

Location

Carver Room

Start Date

4-11-2017 10:00 AM

End Date

4-11-2017 10:20 AM

This document is currently not available here.

Share

COinS
 
Apr 11th, 10:00 AM Apr 11th, 10:20 AM

Simultaneous Determination of 15 Pteridines using Capillary Electrophoresis-- Laser-Induced Fluorescence

Carver Room

Cancer is the second leading cause of death worldwide and it is the cause of about 13% of all deaths worldwide. Deaths from cancer worldwide are projected to continue rising, with an estimated 12 million deaths per year in 2030. Therefore early diagnosis of cancer has become an important task worldwide since it can significantly enhance the cure rate. To achieve early diagnosis of cancers, biomarkers, which are the indicators of existing cancer in human body, must be identified and their correlation with cancer development must be established.

This research project will build upon and validate the previously developed analytical method for the simultaneous determination of a fifteen pteridine panel using our proprietary P-Scan technology. Elevated levels of pteridine derivatives in the urine of women diagnosed with breast cancer has established these molecules as putative biomarkers for early risk screening. However, the sensitivity and accuracy must be improved to minimize false-positive and false-negative rates when it is applied in clinical diagnosis. This expanded biomarker panel study is intended to increase diagnostic accuracy. The impact of this study is that the resulting data and method will broaden the panel of metabolic biomarkers, enabling researchers and clinicians to more accurately characterize tumor biology in cancer patients.